Cargando…
Biomarkers in DILI: One More Step Forward
Despite being relatively rare, drug-induced liver injury (DILI) is a serious condition, both for the individual patient due to the risk of acute liver failure, and for the drug development industry and regulatory agencies due to associations with drug development attritions, black box warnings, and...
Autores principales: | Robles-Díaz, Mercedes, Medina-Caliz, Inmaculada, Stephens, Camilla, Andrade, Raúl J., Lucena, M. Isabel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992729/ https://www.ncbi.nlm.nih.gov/pubmed/27597831 http://dx.doi.org/10.3389/fphar.2016.00267 |
Ejemplares similares
-
Genetic variations in drug-induced liver injury (DILI): resolving the puzzle
por: Stephens, Camilla, et al.
Publicado: (2012) -
Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries
por: Bessone, Fernando, et al.
Publicado: (2022) -
A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
por: Björnsson, Einar S., et al.
Publicado: (2022) -
Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate–Induced Liver Injury in Spanish Patients
por: Stephens, Camilla, et al.
Publicado: (2016) -
Mechanistic Studies of Idiosyncratic DILI: Clinical Implications
por: Uetrecht, Jack
Publicado: (2019)